Abnormal intracellular level of bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients

F. Scamardella, Mariacaterina Maconi, L. Albertazzi, B. Gamberi, L. Gugliotta, M. Brini

Research output: Contribution to journalArticle

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative disease caused by impaired apoptosis regulation that leads to an abnormal survival and an accumulation of B-lymphocytes. Anti-apoptotic Bcl-2 and pro-apoptotic Bax proteins are involved in the highly regulated mechanism of cell death. Bax and Bcl-2 intracellular levels were analyzed both in CD19+ and CD3+ cells from 28 B-CLL de novo patients and compared with cells from healthy donors. Our results were expressed as a ratio (Bax/Bcl-2) obtained by dividing Bax mean fluorescence intensity (MFI) and Bcl-2 MFI; obviously, a lower ratio is associated with an anti-apoptotic status, while a higher index correlates to apoptosis activation. In CD19+ B-CLL cells, the Bax/Bcl-2 ratio was lower than in the CD19+ normal counterpart (1.3 versus 3.51; P <.05), mainly due to a Bcl-2 over expression (17.65 versus 9.02; P <.001). In CD3+ cells from B-CLL patients, the Bax/Bcl-2 ratio was lower than in normal CD3+ cells (7.89 versus 8.96; P <.005), most importantly as a result of Bax suppression (77.22 versus 96.63; P <.001). These study data show an apoptosis inhibition not only in CD19+ cells, but also in CD3+ cells, suggesting a pivotal role of T-cells in B-CLL pathogenesis.

Original languageEnglish
Pages (from-to)187-192
Number of pages6
JournalLaboratory Hematology
Volume12
Issue number4
DOIs
Publication statusPublished - 2006

Keywords

  • Apoptosis
  • B-Cell chronic lymphocytic leukemia
  • Bax
  • Bcl-2
  • Intracellular level

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Abnormal intracellular level of bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients'. Together they form a unique fingerprint.

Cite this